(5-氯-1,3-苯并二恶茂-4-基)氨基甲酸叔丁酯 | 379229-84-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并间二氧杂环戊烯类
• 中文名称: (5-氯-1,3-苯并二恶茂-4-基)氨基甲酸叔丁酯
• 中文别名: (5-氯-1,3-苯并二氧)氨基甲酸叔丁酯
• 英文名称: tert-butyl (5-chloro-1,3-benzodioxol-4-yl)carbamate
• 英文别名: tert-butyl N-(5-chloro-1,3-benzodioxol-4-yl)carbamate；ter-butyl 5-chloro-1,3-benzodioxol-4-ylcarbamate；tert-Butyl (5-chlorobenzo[d][1,3]dioxol-4-yl)carbamate
• CAS: 379229-84-2
• 化学式: C₁₂H₁₄ClNO₄
• 分子量: 271.7
• InChiKey: VGAUUGYGFROFEI-UHFFFAOYSA-N

物化性质

• 密度：
  1.347

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  56.8
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2932999099

反应信息

• 作为反应物：
  描述：

  (5-氯-1,3-苯并二恶茂-4-基)氨基甲酸叔丁酯 在 盐酸 、 三氟乙酸 作用下， 以 二氯甲烷 、 异丙醇 为溶剂， 反应 7.0h， 生成 4-[(5-chloro-1,3-benzodioxol-4-yl)amino]-6-methoxyquinazolin-7-ol
  参考文献：
  名称：

  Discovery of a New Class of Anilinoquinazoline Inhibitors with High Affinity and Specificity for the Tyrosine Kinase Domain of c-Src

  摘要：

  Deregulated activity of the nonreceptor tyrosine kinase c-Src is believed to result in signal transduction, cytoskeletal and adhesion changes, ultimately promoting a tumor-invasive phenotype. We report here the discovery of a new class of anilinoquinazoline inhibitors with high affinity and specificity for the tyrosine kinase domain of the c-Src enzyme. Special attention was directed toward finding inhibitors selective against KDR tyrosine kinase in order to ensure that the in vivo profile of a specific Src inhibitor could be determined. The 4-aminobenzodioxole quinazoline series gave compounds with excellent potency and selectivity. The most interesting compounds were evaluated in vivo and displayed good pharmacokinetics following oral dosing. Compounds such as the aminobenzodioxoles were shown to be potent inhibitors of tumor growth in a c-Src-transformed 3T3 xenograft model in vivo, resulting in more than 90% growth inhibition at doses as low as 6 mg/kg po once daily. Src tyrosine kinase inhibitors such as these may provide a novel therapeutic modality for targeting cancer invasion and metastasis.

  DOI：

  10.1021/jm030317k
• 作为产物：
  描述：

  5-氯-1,3-苯并二噁唑 在 叠氮磷酸二苯酯 、 三乙胺 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 1,4-二氧六环 为溶剂， 反应 4.5h， 生成 (5-氯-1,3-苯并二恶茂-4-基)氨基甲酸叔丁酯
  参考文献：
  名称：

  Discovery of a New Class of Anilinoquinazoline Inhibitors with High Affinity and Specificity for the Tyrosine Kinase Domain of c-Src

  摘要：

  Deregulated activity of the nonreceptor tyrosine kinase c-Src is believed to result in signal transduction, cytoskeletal and adhesion changes, ultimately promoting a tumor-invasive phenotype. We report here the discovery of a new class of anilinoquinazoline inhibitors with high affinity and specificity for the tyrosine kinase domain of the c-Src enzyme. Special attention was directed toward finding inhibitors selective against KDR tyrosine kinase in order to ensure that the in vivo profile of a specific Src inhibitor could be determined. The 4-aminobenzodioxole quinazoline series gave compounds with excellent potency and selectivity. The most interesting compounds were evaluated in vivo and displayed good pharmacokinetics following oral dosing. Compounds such as the aminobenzodioxoles were shown to be potent inhibitors of tumor growth in a c-Src-transformed 3T3 xenograft model in vivo, resulting in more than 90% growth inhibition at doses as low as 6 mg/kg po once daily. Src tyrosine kinase inhibitors such as these may provide a novel therapeutic modality for targeting cancer invasion and metastasis.

  DOI：

  10.1021/jm030317k

文献信息

• [EN] QUINAZOLINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER<br/>[FR] DERIVES DE QUINAZOLINE UTILISES DANS LE TRAITEMENT DU CANCER
  申请人：ASTRAZENECA AB

  公开号：WO2004004732A1

  公开（公告）日：2004-01-15

  The invention concerns quinazoline derivatives of Formula (I) wherein each of Z, m, R1, n, R3,Z2 and R14 have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-invasive or anti-proliferative agent in the containment and/or treatment of solid tumour disease.

  这项发明涉及式（I）的喹唑啉衍生物，其中Z、m、R1、n、R3、Z2和R14中的每一个具有在描述中先前定义的任何含义；它们的制备方法，含有它们的药物组合物以及它们在制造用作抗侵袭或抗增殖剂的药物时在固体肿瘤疾病的控制和/或治疗中的用途。
• [EN] TETRAZOLE AND OXADIAZOLONE SUBSTITUTED beta-AMINO ACID DERIVATIVES<br/>[FR] DERIVES DE beta-AMINOACIDES SUBSTITUES PAR TETRAZOLE ET OXADIAZOLONE
  申请人：WARNER LAMBERT CO

  公开号：WO2004078734A1

  公开（公告）日：2004-09-16

  This invention relates to novel tetrazole and oxadiazalone β-amino acids derivatives of the formula (I, II), wherein G is (III, IV) wherein R1 through R4 are defined as in the specification, pharmaceutical compositions containing them and their use for the treatment of various central nervous system and other disorders. The cyclopropyl β-amino acids derivatives of this invention exhibit activity as alpha2delta ligands (α2δ ligands). Such compounds have affinity for the α2δ subunit of a calcium channel.

  这项发明涉及公式(I, II)的新型四唑和氧代噁唑酮β-氨基酸衍生物，其中G为(III, IV)，其中R1至R4如规范中所定义，含有它们的药物组合物以及它们用于治疗各种中枢神经系统和其他疾病的用途。本发明的环丙基β-氨基酸衍生物表现出作为α2δ配体（α2δ配体）的活性。这类化合物对钙通道的α2δ亚基具有亲和力。
• [EN] SUBSTITUTED 3-CYANOQUINOLINES AS MEK INHIBITORS<br/>[FR] 3-CYANOQUINOLEINES SUBSTITUEES UTILISEES COMME INHIBITEURS DE MEK
  申请人：ASTRAZENECA AB

  公开号：WO2004005284A1

  公开（公告）日：2004-01-15

  The invention concerns quinoline derivatives of Formula (I) wherein each of Z1, m, R1, n, R3, Z2 and R14 have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-invasive or anti-proliferative agent in the containment and/or treatment of solid tumour disease.

  这项发明涉及式（I）的喹啉衍生物，其中Z1、m、R1、n、R3、Z2和R14中的每一个具有在描述中先前定义的任何含义；它们的制备方法，含有它们的药物组合物以及它们在制造用作抗侵袭或抗增殖剂的药物的用途中，用于包含和/或治疗实体肿瘤疾病。
• Cyclopropyl beta-amino acid derivatives
  申请人：——

  公开号：US20040147608A1

  公开（公告）日：2004-07-29

  This invention relates to novel cyclopropyl &bgr;-amino acids derivatives of the formula 1 wherein R 1 through R 4 are defined as in the specification, pharmaceutical compositions containing them and their use for the treatment of various central nervous system and other disorders. The cyclopropyl &bgr;-amino acids derivatives of this invention exhibit activity as alpha2delta ligands (&agr;2&dgr; ligands). Such compounds have affinity for the &agr;2&dgr; subunit of a calcium channel.

  这项发明涉及公式1的新型环丙基β-氨基酸衍生物，其中R1至R4如规范中定义，含有它们的药物组合物以及它们用于治疗各种中枢神经系统和其他疾病的用途。本发明的环丙基β-氨基酸衍生物表现出作为α2δ配体（α2δ配体）的活性。这类化合物对钙通道的α2δ亚基具有亲和力。
• [EN] QUINAZOLINE DERIVATIVES<br/>[FR] DERIVES DE QUINAZOLINE
  申请人：ASTRAZENECA AB

  公开号：WO2002016352A1

  公开（公告）日：2002-02-28

  The invention concerns quinazoline derivatives of Formula (I) wherein each of m, R?1, n, R2 and R3¿ have any of the meanings defined in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-invasive agent in the containment and/or treatment of solid tumour disease.

  本发明涉及式（I）的喹唑啉衍生物，其中m、R1、n、R2和R3中的每一个具有在说明书中定义的任何含义；它们的制备过程，包含它们的制药组合物以及它们在制造用于抗侵袭剂治疗和/或治疗实体瘤疾病的药物中的使用。